98 results
Page 2 of 5
6-K
EX-99.2
u97c6bit 2x2
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.3
5y7vq r264e01
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.2
1csgej hmtr5qepeo
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
3tqtcfexjeefcv
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
4sp41 2yphf
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
nsl9lkte
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
4sdgx8io i0abt
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
zz0mi 5p77rnzx1k
17 Feb 22
Shelf registration (foreign)
4:14pm
F-3
EX-4.1
crlgi37z y7ezh3l
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
sn6okt96 7hx8s
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
424B7
dew9g 4zfplk7jgl2b
23 Nov 21
Prospectus with selling stockholder info
4:06pm
6-K
EX-99.2
kp5kx7xr92 pu0b
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
q45he
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
x53lmp1vvms7
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
hgo77g0
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.2
9d9epuucn92pw4gg6w
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am